Elan drug approved as company narrows losses

THE European Commission has given Elan marketing approval for its drug Prialt, a painkiller derived from a tropical sea snail.

Elan drug approved as company narrows losses

The Irish pharmaceutical company, which saw its share price collapse three years ago due to accounting worries in the group, said yesterday: "Prialt can offer new hope for patients in Europe as the first new IT analgesic approved in more than two decades."

An infusion treatment for severe chronic pain, Prialt achieved US regulatory approval last December.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited